# A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

> **NCT01330316** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 119 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** BI 201335
- **DRUG:** PegIFN/RBV

## Key facts

- **NCT ID:** NCT01330316
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2016-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01330316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01330316, "A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01330316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*